Skip to main content
. 2019 Jan 10;12:6. doi: 10.1186/s13045-018-0696-z

Fig. 1.

Fig. 1

Outcomes of patients receiving first allo-HCT for AITL. a Cumulative incidence of non-relapse mortality. b Cumulative incidence of lymphoma progression/relapse. c Progression-free survival. d Overall survival